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Abstract 
      The incidence of acute myeloid leukemia (AML) is expected to increase in 
conjunction with our ageing population.  Although it is proving to be a heterogeneous 
disease process, the only treatment with proven survival benefit for poor risk AML 
remains allogeneic hematopoietic cell transplant.  Although this is presumed to be a 
curative strategy, many patients relapse after transplant, prompting us to examine 
various ways that we can improve outcomes.  These efforts involve every step of AML 
diagnostics and therapy, including the intricate processes of conditioning, graft 
manipulation and immunomodulation.   The hope is that improvement in these steps will 
ultimately improve survival and decrease relapse rates for AML patients after transplant. 
 
Introduction 
 Allogeneic hematopoietic cell transplantation (allo-HCT) is an important and widely 
used treatment for patients with hematological malignancies, including Acute Myeloid 
Leukemia (AML) and high-risk Myelodysplastic Syndrome (MDS).  An estimated 20,000 
patients receive allo-HCT each year, and while the procedure can be a patient’s sole 
potentially curative option, post-transplant relapse is common.  According to the Center 
for International Bone Marrow Transplant Registry (CIBMTR), relapse rates following 
HLA-matched myeloablative transplantation range from approximately 25% for good-risk 
patients [i.e., AML in first complete remission (CR-1) or Chronic Myeloid Leukemia 
(CML) in chronic phase] to over 60% for poorest risk patients (those transplanted in 
relapse). Factors influencing relapse (for better or worse) can be classified as intrinsic to 
the disease, the allo-HCT preparative regimen, or the interaction between the disease 
and the transplanted immune system. For all of the sophisticated work performed on this 
problem, it is certain that we have only an initial understanding of the elements driving 
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post-HCT AML relapse [1,2].  In this review we outline current strategies to study and 
treat AML relapse after allo-HCT with an emphasis on new innovative investigational 
approaches (Table 1).  While treatment elements designed to reduce relapse can be 
categorized as pre-, intra- or post-HCT strategies, many of these approaches are 
relevant to more than one category. 
 
Prognostic (Biological) AML Markers  
Cytogenetics and Relapse after allo-HCT 
 When considering non-transplant therapy (induction and consolidation) for AML, age, 
cytogenetics and response to therapy remain major predictors of outcome.  Similarly, 
patients with poor-risk cytogenetics are known to fare worse after allo-HCT than patients 
with a more favorable karytotype [3-5]. However, Tallman et al. compared matched 
unrelated allo-HCT in CR1 (261 patients) to those transplanted in second CR (CR2 = 
299 patients), and showed that favorable cytogenetics were associated with improved 
outcome only in CR2 transplants [6].  Importantly, normal cytogenetics confer only 
intermediate (as opposed to favorable) prognosis in adult AML, while the worst risk is 
associated with a monosomal karyotype (MK) or complex cytogenetics ( ≥ 3 anomalies). 
It is this poorest risk group that derives the most benefit in terms of relapse rates and 
survival after allo-HCT [6].   
Sub-Cytogenetic Molecular Changes and allo-HCT Replase 
 A growing number of sub-cytogenetic molecular anomalies have prognostic 
implications before and after allo-HCT in AML.  For example, mutations occurring in the 
core binding factor [t(8:21) and inv 16] or the B23/nucleophosmin (NPM1) locus are 
associated with potential cure following high dose cytarabine regimens, allowing for the 
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avoidance of allo-HCT.  Even so, up to 20-30% of apparent favorable-risk cases carry a 
prevailing c-kit proto-oncogene mutation responsible for decreased overall survival [7].  
 A major target for AML molecular therapy is the FLT3-ITD (internal tandem 
duplication) mutation, which is very common in adult leukemia and causes constitutive 
tyrosine kinase activation. Drafting off the success of imatinib in CML, new tyrosine 
kinase inhibitors (TKIs) such as sorafenib, sunitinib, midostaurin, and more recently 
AC220 and PLX3397 are being used singly or with chemotherapy in AML clinical trials.  
Metzelder et al. treated 3 relapsed/refractory AML patients prior to allo-HCT with 
sorafenib monotherapy.  Two of the patients had remissions followed by allo-HCT [8].  
AC220 is the subject of an ongoing Phase II trial for the treatment of resistant/relapsed 
AML.  Two cohorts are being studied, Cohort 1 includes patients over 60 years who are 
refractory to one therapy, and Cohort 2 has patients over 18 years who are refractory to 
two regimens.  AC220 achieved a composite partial remission (PR) rate of 19% and a 
CR rate of 62%.  Median overall survival (OS) is 24.7 weeks for efficacy evaluable 
patients, 24.1 weeks for Cohort 1, and the data is not complete yet for Cohort 2 
[9].  PLX3397 [10] is also a highly selective inhibitor of FLT3-ITD, c-fms and c-kit that is 
currently being studied at the Fred Hutchinson Cancer Research Center in FLT3 
mutation positive AML refractory to conventional therapy in a phase I clinical trial.  
Compared to the dramatic success in CML, expectations for TKIs in AML are more 
limited, due to the extremely complex molecular etiology and evolution, and rapid 
progression of the acute disease.  Disease stabilization and CRs may be short-lived, 
suggesting that resistance to the drugs develops quickly.  Theoretically, resistance may 
be circumvented by applying concurrent therapies with diverse molecular targets and 
modes of action against the aberrant signal transduction in leukemic blasts. 
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Quality of CR Prior to Allo-HCT and the Effect on Relapse after Allo-HCT 
Complete remission in AML (defined as the presence on bone marrow morphologic 
analysis of less than 5% blasts and normal peripheral counts) remains the goal of 
induction and consolidation chemotherapy, and is an eligibility requirement for transplant 
at most centers performing allo-HCT.  For patients with low-risk disease, as noted 
above, chemotherapy induced CR may be all that is required for cure.  However, for 
intermediate- and poor-risk disease, patients should be referred for allo-HCT, which is 
the sole potentially curative approach. 
Growing evidence supports the conclusion that the prognostic function of the 
morphologic CR can be improved by further qualification.  CR with minimal residual 
disease (MRD) refers to a morphologic blast count <5% with any detectable persistence 
of the leukemic clone.  Evaluation of MRD includes histology techniques with a 1-5% 
limit of detection (LOD) (similar to cytogenetic culture techniques).  Molecular 
approaches to determining MRD include fluorescent in situ hybridization (FISH: up to 
0.5% LOD), flow cytometry analysis (0.1% to 0.01% LOD) [11], or polymerase chain 
reaction (PCR: LOD is the most sensitive, but will vary depending on the specific 
characteristics of the primer set and reaction conditions).  A recent study evaluated the 
presence of MRD (detected by ten color flow cytometry) and the clinical outcomes of 99 
patients who received standard chemotherapy followed by allo-HCT (Fig. 2).  MRD-
positivity was associated with a hazard ratio of 4.05 for overall mortality and an 8.49 
hazard ratio for relapse when compared to the MRD-negative cohort [12]. Similarly, data 
from 254 patients treated at MD Anderson Cancer Center revealed persistance of 
cytogenetic abnormalities at the time of morphologic CR in 28% of cases.  Patients with 
MRD had median relapse free survival (RFS) and OS of 6 months and 11 months, 
compared to median RFS and OS of 21 months and 26 months in patients with normal 
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karyotype at CR.  Patients with persistent cytogenetic abnormalities who underwent 
stem cell transplant had an improved survival compared to those who did not undergo 
transplant (3 year RFS 33% and 9%, OS 33% and 8% respectively) [13]. These data 
underscore the importance of obtaining a CR by the most sensitive analysis.  Therefore, 
although the optimal timing and method of analysis is unclear, MRD is a prognostic 
factor of growing importance. 
 
AML Induction Agents  
 Based on the critical importance of a high-quality CR, induction and consolidation are 
pivotal components of a patients’ success after allo-HCT, however regimen has yet 
demonstrated greater efficacy than the standard three days of anthracycline and seven 
days of cytarabine (so-called “7+3”).  Dose intensity appears critical, since 90 mg/m2 of 
daunorubicin was shown to improve outcomes with minimal additional toxicity compared 
to 45 mg/m2, even in the elderly [14,15].  Importantly, it not yet clear that the improved 
CR rate translates into more patients proceeding to allo-HCT or a superior post-allo-HCT 
relapse rate.  
To improve induction responses, some approaches try to sensitize leukemic blasts to 
standard chemotherapy.  For example, a Phase I study added the hypomethylating 
agent decitabine to standard 7+3 induction as a form of “epigenetic priming”.  Of 30 
patients evaluated, 83% achieved a CR [16].  Further studies are in process to validate 
these findings.  In vitro studies also show a synergistic anti-tumor effect of clofarabine (a 
nucleoside analogue) with cytarabine by increasing intracellular levels of ara-CTP. 
Phase II trials using clofarabine and cytarabine in older AML patients in the relapsed and 
de novo setting demonstrate tolerable side effect profiles, and potentially improved 
outcomes [17,18].   
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Transplant Strategies to Reduce Relapse 
 Allo-HCT may be the best chance for a curative modality for patients with 
intermediate- or high-risk AML (including patients with relapsed disease).  Fear of 
relapse after allo-HCT has prompted studies to improve conditioning regimens through 
intensification, and manipulation of the graft-versus-leukemia (GVL) effect (the rationale 
behind the feasibility of reduced-intensity HCT; Fig. 1).  The challenge is balancing the 
risk of graft-vs-host disease (GVHD) and other causes of transplant related mortality 
(TRM) with relapse.   
Modifications of allo-HCT Conditioning Regimens 
 Modified TBI dosing: A randomized trial of AML in CR1 demonstrated a decreased 
relapse rate of 12% after 15.75 Gy of TBI, compared to 35% after 12 Gy, with similar OS 
[19].  Importantly, patients receiving higher radiation doses also received less GVHD 
immune prophylaxis and therefore had a higher incidence of acute GVHD.  Since the 
GVL effect is thought to accompany GVHD, the decreased relapse rates may have been 
a result of the increased TBI, the increased GVL, or both.  However, patients who 
received higher TBI dosing also had increased rates of transplant related mortality, 
equalizing the overall survival rates between the two groups.   
 Modified Chemotherapy Regimens: Various conditioning regimens continue to be 
tested in an effort to improve allo-HCT outcomes and decrease AML relapse rates.  A 
Phase I/II study transplanted 46 patients with hematologic malignancies and persistent 
disease (31 of which had AML) using clofarabine in combination with myeloablative 
doses of busulfan.  This regimen yielded 100% engraftment and CR in all of the AML 
patients without prior allo-HCT [20].  Overall survival in all patients was 48% at 1 year 
and 35% at 2 years.   Another ongoing trial randomizes patients with advanced 
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AML/MDS to four arms comprised of busulfan in combination of varied doses of 
clofarabine and fludarabine.  All patients treated so far have engrafted, with an 85% CR 
rate at interim analysis [21].  Together, these studies show promising results in patients 
with high risk/refractory AML undergoing transplant, however the effect of these 
regimens on relapse remains to be determined. 
 Radioimmunotherapy: Monoclonal antibodies provide a targeted therapeutic 
approach to hematologic malignancies, best demonstrated by the success of Rituximab 
in non-Hodgkin lymphoma. Antibodies specific to a variety of antigens, (such as CD45, 
an epitope widely expressed on most hematologic tissues), are being investigated as 
targeted radioisotope conditioning regimens for allo-HCT.  Anti-CD45 antibodies 
conjugated to radioiodine deliver radiation specifically to the marrow space, with 
decreased global morbidity in leukemic patients.  A Phase I/II trial performed at the 
FHCRC used this approach in combination with targeted busulfan and 
cyclophosphamide to condition 59 AML patients.  At 3 years, the non-relapse mortality 
was 21% with DFS estimated at 61% [22].  Compared to similar patients from the 
International Bone Marrow Transplant Registry, the hazard of mortality of antibody-
treated patients was 0.65 (95% CI 0.39-1.08; P=.09).  Another study evaluated the 
maximum tolerated dose (MTD) of the 131I-anti-CD45 antibody that can be combined with 
standard reduced-intensity conditioning regimen prior to allo-HCT in older patients with 
advanced AML or high risk MDS.  There was a 12% TRM by day 100, with estimated 1 
year relapse rate of 40% and 1 year survival estimate of 41% [23].  Together, the data 
regarding radiolabeled anti-CD45 antibodies suggest a strategy for specific targeted 
stem cell ablation with the potential to reduce relapse.   
Modulation of the Graft and the GVL/GVHD Effect 
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 Reduced-intensity allo-HCT: Reduced-intensity transplantation (RIT) strategies were 
developed based on the observation that non-twin HLA-identical sibling donors 
conferred a superior relapse free survival compared to identical twin donors, revealing a 
GVL effect.  In time this observation lead to successful experimentation with reduced 
intensity conditioning regimens (non-myeloablative regimens) that relied upon the donor 
immune system to deliver the cell mediated anti-tumor effect.  The reduced intensity 
conditioning, with lower upfront mortality, allowed extension of the upper age limits for a 
patient to receive allo-HCT.  Recent work by Sorror et.al at demonstrated a similar TRM 
among selected patients receiving RIT in a 60-65 year old, 65-70 year old, and 70-75 
year old cohort of patients [24].  Another study evaluated 122 patients with various 
stages of AML conditioned with 2 Gy TBI, either with or without fludarabine, as well as 
cyclosporine and MMF for post-HCT immunosuppression.  Overall 2-year survival was 
48% and DFS was 44% [25]. However, relapse rates at 2 years were still 39% for all 
patients treated.  Similarly, another study of 79 AML patients ≥ 55 years of age used 
non-myeloablative doses of busulfan and fludarabine prior to allo-HCT.  Although these 
patients largely had a good performance status, their one year TRM was around 20%, 
with 2 year overall survival was 46% [26].  Relapse after transplant of all patients was 
estimated around 58%.  Not surprisingly, patients with lower-risk AML prior to allo-HCT 
had improved survival post-transplant.  An additional study used RIT conditioning with 
fludarabine and melphalan in 36 patients considered ineligible for myeloablative allo-
HCT.  These patients had a median age of 57 years and 72% of patients had a co-
morbidity score ≥3.  With a median follow-up of 52 months, OS and PFS rates at 4 years 
were 71% and 68%, respectively.  The 4 year cumulative incidence of non-relapse 
mortality was 20% and importantly, relapse mortality was only 8% [27].  These and other 
studies reveal that reduced-intensity allo-HCT may provide a survival benefit by reducing 
relapse in selected older AML patients with higher co-morbidity scores.  The feasibility of 
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RIT relies heavily on the GVL effect, which often comes with increased risk of GVHD.  
The challenge of maximizing GVL without concurrent immune-mediated end-organ 
damage has driven efforts to manipulate the donor cells with additional immune 
modulation.    
 Graft engineering:  Different immunosuppression regimens and timing have been 
evaluated in an effort to dampen the alloreactive donor T-cell response from the 
transplanted graft.  Unfortunately, it is widely accepted that our inability to specifically 
target the alloreactive response diminishes the global T-cell response and decreases 
GVL.  T-cell depletion and/or removal of specific T-cell subsets can be accomplished in 
vitro pre-transplant with CD34+ cell selection or in vivo after cell infusion with the use of 
the anti-CD52 antibody alemtuzumab.  Jakubowski et al. used T-cell depleted HLA-
matched related PBSC allografts in 52 patients (almost half with AML/MDS) after 
conditioning with fludarabine, thiotepa and hyper-fractionated TBI [28]. In the absence of 
immunosuppression, 3 year disease free survival (DFS) was estimated to be 61% in all 
patients and 3 year OS was estimated to be 62%, with grade 2 acute GVHD detected in 
8% and chronic GVHD in 9% of patients. Only 6 of the AML/MDS patients had 
hematologic or molecular evidence of relapse, suggesting that T-cell depletion may help 
tip the scales in favor of GVL effect.  Although no immune-mediated graft rejection 
occurred, a large proportion of the patients had absolute CD4 counts <200 cells/L for 
more than seven months.  In a related study using HLA-matched unrelated stem cell 
donors, anti-thymocyte globulin (ATG) was added after allo-HCT as GVHD prophylaxis.  
In this case, 34 patients were transplanted with a four year estimated DFS of 56.8% 
among all patients.  Nine percent had grade II-III acute GVHD and 29% had chronic 
GVHD, with only one late graft failure [29].  Only one AML patient relapsed (with poor-
risk cytogenetics), again highlighting the possibility that GVL effect can be maintained 
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while minimizing GVHD and the need for long term immunosuppression.  Additionally, 
the Bone Marrow Transplant Clinical Trials Network transplanted 44 AML patients in 
CR1 or CR2 with chemotherapy/TBI conditioning followed by T-cell depleted grafts from 
HLA-matched donors (no GVHD immune prophylaxis was given).  All patients engrafted 
in this trial, with a 22.7% incidence of acute GVHD grade II-IV, and a 6.8% incidence of 
chronic GVHD at one year.  The 3 year relapse rate for CR1 patients was 17.4%, with a 
58% DFS at 3 years [30].   
 Technically complicated methods have been devised to specifically remove 
alloreactive or naïve T cells from the donor graft.  These strategies have been 
challenging to transition to the clinical setting, but provide potential for mitigating GVHD 
[31,32].  Another strategy for depleting alloreactive T-cells involves a large dose of 
cyclophosphamide early after the infusion of a T-cell replete graft.  This reduced the 
incidence of severe GVHD in haploidentical HLA matched transplant recipients [33]. 
Alternatively, the introduction of an inducible suicide gene, could cause self-destruction 
of alloreactive T cells, while potentially maintaining GVL effect.  These strategies may 
potentially maintain the integrity of the immune mediated prevention of relapse while 
minimizing the morbidity and mortality associated with GVHD.  
 
Relapse Management and Maintenance Strategies after allo-HCT 
 Return of AML after transplant is of ominous portent, and relapse is fatal in the 
majority of patients.  Commonly, the first maneuver is to reduce immunosuppression to 
stimulate any potential GVL effect, however this can be a great challenge to the patient 
and clinician when faced with concomitant GVHD.  Donor lymphocyte infusion (DLI) can 
be employed as a post-HCT infusion of a reserved portion of donor cells, intended to 
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induce a GVL effect during relapse.  Also discussed in this section are emerging new 
techniques applied after allo-HCT to further prevent relapse and improve outcomes.  
Donor Lymphocyte Infusion 
 The role of DLI after allo-HCT for AML is not well defined.  For reasons likely 
attributable to the rapid natural history of AML relapse, the administration of additional 
donor cells result in relatively low response rates, since DLI may require a prolonged 
time to be effective [2].  Nevertheless, as previously mentioned, there has been ample 
evidence of a GVL effect against AML post allo-HCT.  This is inferred from the 
observation that allo-HCT recipients from syngeneic donors (lacking significant antigenic 
disparity) have a higher relapse rate, and additional evidence that GVHD is associated 
with a lower relapse rate [34].  It is interesting, therefore, that a large prospective 
randomized trial showed similar relapse rates for AML patients who were transplanted 
with T-cell depleted grafts versus unmanipulated grafts from unrelated donors [35].  
 Two large retrospective analyses published estimated a response rate of 15-29% for 
AML relapse treated with DLI [36,37]. Interestingly, many of these patients relapse with 
extramedullary disease, suggesting areas that are sanctuary sites [38].  A European 
Group for Blood and Marrow Transplantation retrospective analysis surveyed 399 
relapsed AML patients, in which 171 received DLI (including those who received 
mobilized PBSC or marrow concentrates), and 75% received chemotherapy prior to the 
infusion. The estimated 2-year survival in the DLI group was 21% versus 9% in the 
untreated cohort, and fewer patients from the DLI group were sent to a second 
transplant procedure.  Factors associated with improved outcomes by univariate 
analysis included: age <37 years, relapse later than 5 months after allo-HCT, and the 
use of DLI. Favorable elements on multivariate analysis included: female sex, favorable 
cytogenetics, remission at time of DLI, and less than 35% bone marrow blasts. Thirty-
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five of 106 DLI patients with active leukemia achieved complete remission.  Remarkably, 
acute GVHD was associated with a poorer outcome, however chronic GVHD was linked 
to improved outcomes [39].  These results suggest that DLI can improve survival  in the 
setting of relapse after allo-HCT, likely due to an intensified GVL effect which is often 
accompanied by chronic GVHD.  
 Augmented DLI: DLI strategies have included co-administration of 
immunomodulatory cytokines or chemotherapy to reduce relapse.  Levine et al. treated 
65 patients with relapsed AML using augmented cytarabine based chemotherapy prior to 
DLI.  Median time to relapse was 100 days after allo-HCT in these patients, and the 
median period between relapse and DLI was 19 days.  Forty-two percent of patients 
achieved a CR with DLI, yet only 14% were in CR at 29 months after infusion.  The most 
important predictor of OS was the time from allo-HCT to relapse [40]. This approach 
seemed to provide temporary disease control in the setting of post-transplant relapse.  
However the prognostic importance of time to relapse is a surrogate for the aggressive 
nature of AML, which may outpace the GVL effect of DLI.  Donor lymphocyte priming 
has been investigated using ex vivo activation of the DLI product with the intent of further 
augmenting GVL.  While the technique can be labor intensive and costly, there have 
been small studies applying this approach in humans.  Porter et al. used anti-CD3 and 
anti-CD28 coated beads for ex-vivo co-stimulation of donor T-cells.  Eighteen patients 
were treated with conventional DLI, followed by activated product in escalating doses.  
Eight patients achieved CR, including 2/4 patients with AML [41].  Future targets for 
donor lymphocyte priming could generate tumor specific T-cells using peptides specific 
to myeloid blasts, such as PR1 and WT1.   
 Alternate DLI Timing:  Prophylactic DLI (infusion prior to clinical evidence of relapse) 
has been employed following allo-HCT for AML.  Schmid et al. planned prophylactic DLI 
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for day 120 following reduced-intensity allo-HCT for high risk AML or MDS.  However, 
only 12 of 75 patients were eligible at that time due to relapse or sustained GVHD 
requiring immunosuppression [42]. However, of these 12 patients, only two had 
relapsed, with the rest of the patients remaining in CR, with a median follow-up of 31.5 
months after allo-HCT.  In contrast, prophylactic DLI was administered after full intensity 
T-cell depleted allogeneic transplants with promising results by Kobbe et al.  Seventy-
four percent of 14 patients with AML/MDS showed disease-free survival at one year, 
with minimal GVHD [43].  Of the 6 AML/MDS patients who died, three had relapsed.  
Currently, it is unclear whether prophylactic DLI is a feasible approach that significantly 
improves relapse rates after allo-HCT.  
 Targeted tyrosine kinase inhibitors pre and post-HCT for AML: As discussed in the 
pre-transplant section of this article, the tyrosine kinase inhibitors (TKI) sorafenib, 
sunitinib, midostaurin, PLX3397, and AC220 have been used singly or in combination 
with chemotherapy in adult AML, targeting c-Kit and FLT3 mutations.  An exciting 
potential maneuver after allo-HCT has been the use of TKIs as relapse treatment or 
maintenance therapy, vis a vis Imatinib after allo-HCT for CML.  In the work by 
Metzelder and colleagues, 2 of 3 patients treated sorafenib after allo-HCT survived 216 
and 221 days, and the other remained in molecular remission at the time of publication 
[8].  However, Sharma et al. also treated 16 post-HCT relapsed patients with the FLT3-
ITD mutation with sorafenib alone or in combination with systemic chemotherapy.  None 
of these advanced patients achieved a CR, and while 3 patients achieved a partial 
remission, the median OS of these patients was only 83 days, with no one surviving 
longer than 1 year [44].  AC220 is a second generation FLT3 inhibitor that is thought to 
be more specific and potent than sorafenib, with ongoing studies evaluating its efficacy 
as prophylaxis for relapse after allo-HCT. 
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 Epigenetic modifiers peri-transplant: 5-azacitidine and decitabine are 
hypomethylating agents used in the treatment of de novo MDS and AML, and they may 
have a role for relapse prophylaxis or treatment after allo-HCT.  5-azacitidine is thought 
to promote blast differentiation and increase the GVL effect by upregulating HLA-DR1 
and other tumor associated antigens [45,46].  Pre-clinical data from Choi et al. suggests 
that hypomethylating agents induce the activation of regulatory T-cells, suppressing 
GVHD while preserving GVL in mice [47].  Moreover, in humans with relapsed AML after 
allo-HCT, a retrospective analysis of 10 patients revealed that treatment with 5-
azacitidine in this setting induced CR in 6 patients and stabilized disease in 1 patient, 
with no GVHD flares observed.  To date, median OS for the group was >400 days 
suggesting that this approach may be important for managing relapse in these high-risk 
post-HCT patients [48].  De Lima et al. treated 45 patients with MDS or AML using 
various doses of 5-azacitidine as maintenance after allogeneic HCT.  Although median 
follow-up was only 20.5 months at the time of publication, the 1-year event-free and OS 
proved encouraging at 58% and 77% respectively, providing support for further studies 
[49].  Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase (HDAC) inhibitor, may 
also have activity against AML and has the potential to prevent allo-HCT relapse in 
future approaches.  A Phase I study investigated the safety of the HDAC inhibitor without 
allo-HCT in 41 leukemia patients, 31 of which had AML.  Seven patients had 
hematologic improvement (reduction of blasts by >50%), including 2 CR and 2 CR with 
incomplete count recovery.  All of the responding patients had AML, treated at or below 
the maximum tolerated dose, perhaps paving the way for exploration of HDAC inhibitors 
in the setting of relapse prophylaxis [50].  
 
Vaccine Therapy for AML 
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 Research is ongoing to manipulate the recipient or donor immune response, so that 
tumor specific antigens are recognized and targeted.  Various antigen, APC and 
cytokine stimulants are being tested to promote a lasting immune response in the setting 
of relapsed leukemia or MRD after transplant.  This challenge is compounded by 
cancer’s ability to evade ones native immunity via down regulation of tumor antigens, 
MHC complexes or costimulatory molecules [51].   
 WT-1 (Wilm’s Tumor gene) and PR1 have been the predominant antigens targeted 
for leukemia vaccine development. WT-1 codes for a transcription factor that has been 
shown to be over-expressed in myeloid leukemias and involved in cell proliferation 
[52,53].  Mailander et al. reported a promising CR after an HLA-A2 patient with relapsed 
AML was treated with a combination vaccine that included WT-1 peptide primed T-cells 
combined with a T-helper protein and GM-CSF [54].  The same group then treated 17 
AML and 2 MDS HLA-A2 positive patients with a WT-1 peptide vaccine in a Phase II 
trial.  Ten patients maintained stability of their disease, including 4 patients with stable 
disease, with more than 50% blast reduction and one patient obtained CR.  Significantly, 
these results correlated with demonstrable increase in WT-1 specific T-cells and 
decreased WT-1 mRNA [55].  Rezvani et al. treated 8 patients with myeloid 
malignancies using a combination vaccine against both WT-1 and PR1 peptides.  After 
one vaccination, peptide specific T-cells increased and WT-1 and PR1 mRNA 
decreased.  However, subsequent vaccination led to rapid loss of high-avidity peptide 
specific CD8+ cells, correlating to loss of clinical response [56].  
 Unfortunately, vaccine trials have not produced prolonged, clinically significant 
improvement of AML to date, and their role in relapse prevention remains unknown.  
Several questions remain regarding the optimal antigen, effector cell, timing or cytokine 
adjuncts that may produce a durable specific response.  In the setting of HLA-matched 
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allo-HCT, minor histocompatability antigens may also be a potential target for stimulating 
a GVL effect.  Minor histocompatability antigens such as HA-1 and HA-2 expressed 
exclusively on hematopoietic derived cells of the recipient could be targets of reactive T-
cells [57].  Li et al. infused memory T-cells from donors vaccinated against a single 
minor histocompatability antigen (H60) expressed by leukemia cells. This strategy 
showed a promising GVL effect in a mouse model of CML [58].  Currently Phase I/II 
trials are underway to evaluate the potential role of peptide vaccines for myeloid 
malignancies in the post-HCT setting, and results are eagerly anticipated. 
 
Conclusions  
 The landscape of AML treatment and relapse prevention after allogeneic HCT 
continues to evolve with advancing developments using a variety of novel approaches.  
We are discovering that every step of the disease treatment is essential in decision 
making and improving the chances of survival.  Cytogenetic and molecular mutations 
greatly affect response to induction, as well as relapse rates and success after 
transplant.  Our attempt to manipulate the balance between GVL and GVHD via ex vivo 
graft modification and vaccines proves to be arduous and costly.  However, advances in 
conditioning regimens, graft engineering, vaccines, and epigenetic modifiers have 
provided insight into the future of allo-HCT for AML, with a promise of significantly less 
relapse.  
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Figure 1: Conditioning Regimens for allo-HCT (figure courtesy of H.J. Deeg).[2] 
 
 
 
Figure 2. Estimates of the probability of overall survival and disease-free survival for 
AML CR1 patients with negative versus positive MRD via multi-parametric flow 
cytometry results pre-allo-HCT.[12]  
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Table 1.  Strategies to Reducing Relapse in AML patients after allo-HCT 
Determine Pre-Treatment Prognostic Factors 
 Cytogenetic Risk Stratification 
 Molecular Mutation Analysis 
Improve Induction 
 Increase CR Rates: maximize 7+3, “epigenetic priming” and TKIs 
 Deeper CR Rates 
Determine Post-Treatment Prognostic Factors 
 Optimize Timing and Method of MRD Detection 
Transplant Strategies 
 Modify TBI and/or chemotherapy 
 Targeted Radioimmunotherapy 
 Reduced Intensity Transplantation 
 Graft Engineering: maximize GVL vs GVHD 
 Prophylactic TKIs and epigenetic modifiers to prevent relapse 
Relapse Treatment Options 
 Optimize DLI timing and adjuncts 
 Vaccine Therapy 
